• 
  A Brief Overview of Emerging Target: STEAP Xiaobin
  July 11, 2025
  As the "low-hanging fruit" in drug discovery becomes increasingly scarce, pharmaceutical companies are shifting their focus toward novel targets. At this year's AACR Annual Meeting, AstraZeneca unveiled preclinical data for AZD0516, a drug candidate targe
• 
  2025 Q1: Oncology Business Competition Among MNCs Xiaobin
  June 04, 2025
  How did MNCs fare in the oncology field during Q1 of this year?
• 
  Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
  April 28, 2025
  This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.

• 
  Meeting global quality standards: A look at CNS & cardiovascular APIs Suzanne Elvidge
  August 22, 2025
  Active pharmaceutical ingredients (APIs) are the active ingredients used in pharmaceutical manufacturing and are formulated with excipients to create the finished drug form.

• 
  Who Will Hold the Reins? An Analysis of Drug-Originating Countries for the US Market N55.6761
  June 19, 2025
• 
  From Molecule to Market: Innovations Accelerating the Future of Drug Development Annie Roys
  September 04, 2025
• 
  Alzheimer’s Disease: Charting the Course from Plaques to Promise Muhammad Farhan Khalid
  May 28, 2025
  New Tools，New Hope，New Frontier

• 
  Popular Products and Companies at PharmaSources.com (July 2025) PSI
  July 24, 2025
  Popular Products and Companies at PharmaSources.com
• 
  The Bitter Medicine is Good for Health: Research Progress on the Components and Pharmacological Activities of Coptis Chinensis Xiaomichong
  July 02, 2025
• 
  Popular Products and Companies at PharmaSources.com (January 2025) PSI
  January 15, 2025

• 
  Apeloa Pharmaceutical releases first ESG PharmaSources
  May 12, 2025
  Apeloa Pharmaceutical has released its first sustainability report. Apeloa’s 2024 Environmental, Social and Governance (ESG) report marks the start of continuous and responsible disclosure into the future.